Liberation Labs, Vivici partner to expand footprint in USA with new facility

USA – Liberation Labs, company focused on precision fermentation, has partnered with Vivici to produce Vivici’s flagship ingredient, Vivitein BLG, at its Richmond, Indiana facility when commercial production begins in 2026.

Liberation Labs plans to construct its first commercial-scale, purpose-built, precision fermentation biomanufacturing facility with a capacity of 600,000 liters and a fully dedicated downstream process (DSP).

According to the company, the plant is poised to produce a range of bio-based materials, including building block ingredients for food, chemicals, and other industrial products, at scale. This comes amid the increasing demand from consumer packaged goods (CPG) companies and other industrial manufacturers.

Mark Warner, founder and CEO of Liberation Labs, said, “Vivici is a perfect reference case for our facility – a company seeking cost-effective and sustainable manufacturing of a novel protein ingredient that unlocks a range of other healthy and innovative products. We love what Vivici is doing and will be proud to play a role in their success.”

The New Standard of Protein, Vivitein BLG is a dairy protein (beta-lactoglobulin) produced through precision fermentation enabling B2B customers to launch disruptive, differentiated and better overall products to consumers in the US market.

These include clear water-based protein drinks with innovative flavors, clean protein powders with superior muscle-building performance and rapid absorption and vegan-friendly protein bars with luscious chewy textures.

Stephan van Sint Fiet, CEO of Vivici, said, “As awareness of the important role protein plays in supporting active lifestyles continues to grow, American consumers are demanding higher quality and greater quantities of protein in their diets.

“Our partnership with Liberation Labs expands our European manufacturing capabilities, providing US customers with increased supply security for Vivitein™ BLG.”

 Vivici secures US$34M to expand dairy operations

 Recently, Vivici raised a €32.5 million (US$34 million) Series A round to support its expansion and entry into the lactoferrin market.

 According to a report by AgFunderNews, the investment will help Vivici access new markets and build long-term manufacturing capabilities.

CEO Stephan van Sint Fiet noted that the company has already secured its first offtake agreements for beta-lactoglobulin, positioning itself for further growth.

The Netherlands-based company has been rapidly scaling production of beta-lactoglobulin and plans to introduce bovine lactoferrin, a high-value protein with multiple health benefits, in the second half of 2025.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE